Introducing Science + Precision to Botanical Ingredients
Research Drives Discovery
From the characterization and stability of our complex hemp extracts, to in-depth in vitro RNA-seq analyses, our research initiatives illuminate the intricate world of cannabinoids. Cultivate’s groundbreaking pharmacokinetic, safety, and efficacy studies are conducted in collaboration with esteemed researchers at institutions such as Cornell University, Washington State University, and Johns Hopkins Medical. As leaders in cannabinoid exploration, our commitment to advancing therapeutic understanding remains unwavering. This mission extends to advancing our science discoveries with other botanicals that show promise to human and animal health.
Characterization
In partnership with the University of Colorado, Boulder, and Tel Aviv University we’ve achieved complete characterization of our patented extract. Our complex hemp extract, predominantly cannabinoid acids, reveals terpenes, distinct flavonoids, plant lipids, and unique unidentified cannabinoids. All of these components potentially contribute to the therapeutic potential of each unique plant extract.
Full Characterization
Stability
Defying common beliefs in cannabinoid research, our findings challenge the notion that cannabinoid acids are unstable. Contrary to common belief, We’ve demonstrated the exceptional stability of not only CBDA, but also CBGA, CBCA, and THCA within our exclusive patented formulations.
The Cannabinoid Acids Were Shown to be Stable
This product is highly stable through an 8-month period with a 5% (by weight) decarboxylation of total cannabinoid content after 15 months.
More significant decarboxylation is observed after two years, with 12% (by weight) decarboxylation of total cannabinoid content at 27 months.
Unraveling the Physiological Effects of Our Biologically Active Extracts
In vitro research, we are aiming to discern the physiological effects of the biologically active compounds present in our extracts. This focused exploration seeks to identify and understand the intricate ways in which these compounds interact with cellular processes. By unraveling the physiological impact at the cellular level, we aim to pave the way for a deeper comprehension of the therapeutic potential inherent in our formulations.
RNA-seq Analysis
Source: Ric Scalzo Institute for Botanical Research
Genomic studies performed with Sonoran University’s Ric Scalzo Institute for Botanical Research
In collaboration with Ric Scalzo Institute for Botanical Research, we utilize RNA-seq analysis to examine the messenger RNA (mRNA) in our samples, assessing its differential expression. Notably, changes in mRNA expression are unlocking unique and novel pathways signifying potential biological significance. Our findings utilizing cannabinoid acids are offering valuable insights into the functional impact on multiple cellular processes involved in human and animal diseases.
Potential Implications for Neural Function
Preliminary findings suggest an impact on neurotransmitters such as Dopamine and Glutamate, signaling potential implications for neural function. Furthermore, our investigation reveals modulation in pathways associated with inflammation and neoplasia, shedding light on the intricate ways in which our samples influence critical cellular processes. These insights mark significant progress in understanding the potential therapeutic effects of our formulations at a molecular level.
Venn diagram of unique gene expression between the acids compared to CBD isolate
Source: Ric Scalzo Institute for Botanical Research
Bioavailability
At Cultivate Biologics, we are unraveling the complexities of cannabinoid extract bioavailability. Through human pharmacokinetic studies at Washington State University (WSU) and Johns Hopkins University (JHU), as well as a wide range of cross-species pharmacokinetic studies, we’ve discovered the superior absorption of cannabinoid acids. Our research also highlights the nuanced nature of absorption and metabolism across different species which is significant.
CBDA is Absorbed 45x Greater Than CBD
Given equal doses of CBD and CBDA, the acidic form absorbs 45 times greater than the CBD. CBDA also reaches its highest CMax level thirty minutes prior to CBD.
Cultivate Leads in Cannabinoid Research Across Species
Absorption & Metabolism Vary Dramatically Across Species
In Cultivate’s patented formulation CBDA has shown to have 45-times greater bioavailability than CBD isolate in humans. This is not unique to humans, and we’ve found this to be true across multiple species. More interestingly our CBDA enriched cannabinoid formulations have shown efficacy in multiple indications in the canine model. Cultivate’s experience in clinical research specific to full spectrum cannabinoid extracts is leading the way in terms of developing cannabinoid-based human and animal therapies.
- Cannabidiol and cannabidiolic acid: Preliminary in vitro evaluation of metabolism and drug–drug interactions involving canine cytochrome P-450, UDP-glucuronosyltransferase, and P-glycoprotein – July 2023. View Study (PDF)
- Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs – July 2022. View Study (PDF)
- Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in OA Dogs – July 2018. View Study (PDF)
